Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any non-syndromic X-linked intellectual disability in which the cause of the disease is a mutation in the ZNF711 gene.
Features include always present findings: Moderate intellectual disability and Intellectual disability; and very common findings: Delayed speech and language development. 11 total HPO annotations.
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 2:11 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 4 | Moderate intellectual disability, Delayed speech and language development, Autistic behavior |
Head and neck | 2 | Long face, Broad face |
ZNF711 function has not been fully characterized.
Intellectual disability, X-linked 97 is associated with mutations in the ZNF711 gene on chromosome X.
Genetic testing for ZNF711 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for intellectual disability, X-linked 97 has been reported in the published literature.
Phenotype severity distribution: 2 always present features, 1 very common feature, 5 common features.
No clinical trials have been registered for intellectual disability, X-linked 97.
29 publications have been identified in PubMed for intellectual disability, X-linked 97. Research spans Basic Science / Preclinical (28%), Review / Meta-Analysis (17%), and Epidemiology / Natural History (17%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 8 | 28% |
Research summaries | 5 | 17% |
Disease patterns and progression | 5 | 17% |
Testing and diagnosis research | 4 | 14% |
Clinical study results | 4 | 14% |
Other research | 1 | 3% |
Patient case studies | 1 | 3% |
New treatment approaches | 1 | 3% |
McLennan Y (2026). [PMID: 41351347](https://pubmed.ncbi.nlm.nih.gov/41351347/). *Mov Disord*. [Other]
Booalizadeh P (2026). [PMID: 42213295](https://pubmed.ncbi.nlm.nih.gov/42213295/). *J Mol Neurosci*. [Basic Science / Preclinical]
Martin KE (2026). [PMID: 41905555](https://pubmed.ncbi.nlm.nih.gov/41905555/). *J Mol Diagn*. [Diagnostic / Biomarker]
Benzoni C (2026). [PMID: 41667276](https://pubmed.ncbi.nlm.nih.gov/41667276/). *J Neurol Neurosurg Psychiatry*. [Epidemiology / Natural History]
Jost C (2026). [PMID: 41606215](https://pubmed.ncbi.nlm.nih.gov/41606215/). *Eur J Hum Genet*. [Basic Science / Preclinical]
Savvidou A (2026). [PMID: 41980228](https://pubmed.ncbi.nlm.nih.gov/41980228/). *Neurology*. [Epidemiology / Natural History]
Cheves E (2026). [PMID: 39586999](https://pubmed.ncbi.nlm.nih.gov/39586999/). *Journal of autism and developmental disorders*. [Epidemiology / Natural History]
Smolyarchuk EA (2026). [PMID: 41705613](https://pubmed.ncbi.nlm.nih.gov/41705613/). *Terapevticheskii arkhiv*. [Clinical Trial Publication]
Byiers B (2026). [PMID: 41340519](https://pubmed.ncbi.nlm.nih.gov/41340519/). *Journal of intellectual disability research : JIDR*. [Review / Meta-Analysis]
Kourdougli N (2025). [PMID: 38950809](https://pubmed.ncbi.nlm.nih.gov/38950809/). *Biological psychiatry*. [Basic Science / Preclinical]